Journal Article Epublish
PubMed: 39594201 DOI: 10.3390/diagnostics14222533
Proteomic Profiling of COVID-19 Patients Sera: Differential Expression with Varying Disease Stage and Potential Biomarkers.
Diagnostics (Basel) 14(22)
Authors: Iman Dandachi, Ayodele Alaiya, Zakia Shinwari, Basma Abbas, Alaa Karkashan, Ahod Al-Amari, Waleed Aljabr
Affiliations
- Research Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
- Cell Therapy & Immunobiology Department, King Faisal Specialist Hospital and Research Centre, Riyadh 12713, Saudi Arabia.
- Department of Biological Sciences, College of Science, University of Jeddah, Jeddah 21959, Saudi Arabia.
- Department of Basic Medical Sciences, College of Medicine, Dar Al-Uloom University, Riyadh 13314, Saudi Arabia.
- Public Health Authority, Riyadh 13352, Saudi Arabia.
- Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK.
Abstract
: SARS-CoV-2 is one of the viruses that caused worldwide health issues. This effect is mainly due to the wide range of disease prognoses it can cause. The aim of this study is to determine protein profiles that can be used as potential biomarkers for patients' stratification, as well as potential targets for drug development. : Eighty peripheral blood samples were collected from heathy as well as SARS-CoV-2 patients admitted at a major tertiary care center in Riyadh, Saudi Arabia. A label-free quantitative mass spectrometry-based proteomic analysis was conducted on the extracted sera. Protein-protein interactions and functional annotations of identified proteins were performed using the STRING. : In total, two-hundred-eighty-eight proteins were dysregulated among all four categories. Dysregulated proteins were mainly involved in the network map of SARS-CoV-2, immune responses, complement activation, and lipid transport. Compared to healthy subjects, the most common upregulated protein in all three categories were CRP, LGALS3BP, SAA2, as well as others involved in SARS-CoV-2 pathways such as ZAP70 and IGLL1. Notably, we found fifteen proteins that significantly discriminate between healthy/recovered subjects and moderate/under medication patients, among which are the SERPINA7, HSPD1 and TTC41P proteins. These proteins were also significantly downregulated in under medication versus moderate patients. : Our results emphasize the possible association of specific proteins with the SARS-CoV-2 pathogenesis and their potential use as disease biomarkers and drug targets. Our study also gave insights about specific proteins that are likely increased upon infection but are likely restored post recovery.
MeSH
Pharmaceutical Preparations, Biomarkers, Covid-19, Proteomics